Overview

Evaluating the Safety and Tolerability of OraVescent Fentanyl for Opioid Tolerant Patients With Noncancer Related Breakthrough Pain

Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to evaluate the safety and tolerability of OraVescent fentanyl for the potential treatment of breakthrough pain episodes in patients who have chronic noncancer pain.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Cephalon
Treatments:
Fentanyl
Criteria
Inclusion Criteria:

- Chronic pain diagnosis

- Opioid tolerant

- Has on average 1-4 breakthrough pain episodes per day

Exclusion Criteria:

- Drug abuse history

- Cardiopulmonary disease

- Monoamine oxidase inhibitors (MAOIs)

- Expected to have surgery to relieve the pain